- Home
- DBD vs CGON Comparison
DBD vs CGON Comparison
Compare DBD & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBD
- CGON
- Stock Information
- Founded
- DBD 1859
- CGON 2010
- Country
- DBD United States
- CGON United States
- Employees
- DBD 21000
- CGON N/A
- Industry
- DBD EDP Services
- CGON
- Sector
- DBD Technology
- CGON
- Exchange
- DBD Nasdaq
- CGON NYSE
- Market Cap
- DBD 1.9B
- CGON 2.1B
- IPO Year
- DBD N/A
- CGON 2024
- Fundamental
- Price
- DBD $55.32
- CGON $26.23
- Analyst Decision
- DBD Strong Buy
- CGON Strong Buy
- Analyst Count
- DBD 2
- CGON 10
- Target Price
- DBD $65.00
- CGON $64.44
- AVG Volume (30 Days)
- DBD 198.5K
- CGON 781.7K
- Earning Date
- DBD 08-06-2025
- CGON 08-07-2025
- Dividend Yield
- DBD N/A
- CGON N/A
- EPS Growth
- DBD N/A
- CGON N/A
- EPS
- DBD N/A
- CGON N/A
- Revenue
- DBD $3,696,800,000.00
- CGON $662,000.00
- Revenue This Year
- DBD $2.02
- CGON N/A
- Revenue Next Year
- DBD $1.96
- CGON $25,206.93
- P/E Ratio
- DBD N/A
- CGON N/A
- Revenue Growth
- DBD N/A
- CGON 224.51
- 52 Week Low
- DBD $34.38
- CGON $14.80
- 52 Week High
- DBD $55.43
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- DBD 78.20
- CGON 50.40
- Support Level
- DBD $51.46
- CGON $25.24
- Resistance Level
- DBD $52.30
- CGON $26.59
- Average True Range (ATR)
- DBD 1.05
- CGON 1.10
- MACD
- DBD 0.24
- CGON -0.12
- Stochastic Oscillator
- DBD 95.79
- CGON 29.83
About DBD Diebold Nixdorf Incorporated Common stock
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA), followed by the Americas and the Asia-Pacific region.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.